B of A Securities Raises Taysha Gene Therapies Target to $10.00

Key Facts

1B of A Securities raised the price target for Taysha Gene Therapies to $10.00 while maintaining a Buy rating.

2GuruFocus indicated the stock is significantly overvalued with $0.9 million in recent insider stock divestments.

Amid ongoing optimism in the gene therapy sector, B of A Securities raised its price target for Taysha Gene Therapies to $10.00 while maintaining a Buy rating. However, GuruFocus reports indicate the stock is currently significantly overvalued, highlighting a divergence in analyst sentiment. Furthermore, recent insider stock divestments totaling $0.9 million have been recorded, which may prompt caution among retail investors regarding the stock's near-term trajectory.

Contextually, TSHA faces valuation headwinds relative to its biotech peers; market data shows similar firms trading at lower multiples given the high-interest-rate environment. Per market data, the gap between the new price target and current levels reflects confidence in upcoming clinical milestones, though the $0.9 million in insider selling is often viewed as a tactical signal of perceived peak valuation by company leadership.

TSHA shares closed at $6.42 (close June 18, 2026), fluctuating between a high of $6.57 and a low of $6.24 according to market data. Traders should watch for broader market volatility following the Fed's decision on June 17 to hold interest rates at 3.75%, which impacts funding costs for growth-stage biotech firms. Upcoming macroeconomic catalysts will be critical in determining if the stock can bridge the gap toward its $10.00 target.